The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: Potential role in atherogenesis and renal vascular rarefaction

Journal of Immunology

Volumn 185, Issue 7, 2010, Pages 4457-4469

  Thacker, Seth G ^a   Berthier, Celine C ^a   Mattinzoli, Deborah ^b   Rastaldi, Maria Pia ^b   Kretzler, Matthias ^a   Kaplan, Mariana J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; JANUS KINASE; RECOMBINANT ALPHA2B INTERFERON; STAT2 PROTEIN; STAT6 PROTEIN; VASCULOTROPIN A; INTERLEUKIN 1 RECEPTOR; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BRAIN VASCULITIS; CAPILLARY DENSITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CELL STRUCTURE; CIRCULATING ANGIOGENIC CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FEMALE; FUNCTIONAL STATUS; GENE REPRESSION; GENETIC TRANSCRIPTION; GLOMERULUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; KIDNEY BIOPSY; KIDNEY BLOOD VESSEL; KIDNEY FUNCTION; KIDNEY PARENCHYMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; RNA ISOLATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR SURGERY; ADULT; BIOSYNTHESIS; CELL DIFFERENTIATION; DNA MICROARRAY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEM CELL; VASCULARIZATION;

ADULT; ATHEROSCLEROSIS; CELL DIFFERENTIATION; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, INTERLEUKIN-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77958144092     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001782     Document Type: Article

References (133)

1. Herrmann, M., R. E. Voll, and J. R. Kalden. 2000. Etiopathogenesis of systemic lupus erythematosus. Immunol. Today 21:424-426.
2. Bagavant, H., and S. M. Fu. 2005. New insights from murine lupus: disassociation of autoimmunity and end organ damage and the role of T cells. Curr. Opin. Rheumatol. 17:523-528.
3. Grande, J. P. 1998. Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus 7:604-610.
4. Kao, A. H., J. M. Sabatine, and S. Manzi. 2003. Update on vascular disease in systemic lupus erythematosus. Curr. Opin. Rheumatol. 15:519-527.
5. Ward, M. M. 1999. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42:338-346.
6. Haider, Y. S., and W. C. Roberts. 1981. Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am. J. Med. 70:775-781.
7. Hosenpud, J. D., A. Montanaro, M. V. Hart, J. E. Haines, H. D. Specht, R. M. Bennett, and F. E. Kloster. 1984. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am. J. Med. 77:286-292.
8. Rahman, P., M. B. Urowitz, D. D. Gladman, I. N. Bruce, and J. Genest, Jr. 1999. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J. Rheumatol. 26:2363-2368.
9. Esdaile, J. M., M. Abrahamowicz, T. Grodzicky, Y. Li, C. Panaritis, R. du Berger, R. Côte, S. A. Grover, P. R. Fortin, A. E. Clarke, and J. L. Senécal. 2001. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44:2331-2337.
10. Baraczka, K., K. Nékám, T. Pozsonyi, L. Jakab, M. Szongoth, and M. Seszták. 2001. Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement. Neuroimmunomodulation 9:49-54.
11. Denny, M. F., S. Thacker, H. Mehta, E. C. Somers, T. Dodick, F. J. Barrat, W. J. McCune, and M. J. Kaplan. 2007. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110:2907-2915.
12. Rajagopalan, S., E. C. Somers, R. D. Brook, C. Kehrer, D. Pfenninger, E. Lewis, A. Chakrabarti, B. C. Richardson, E. Shelden, W. J. McCune, and M. J. Kaplan. 2004. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103:3677-3683.
13. Celermajer, D. S., K. E. Sorensen, V. M. Gooch, D. J. Spiegelhalter, O. I. Miller, I. D. Sullivan, J. K. Lloyd, and J. E. Deanfield. 1992. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115.
14. Lee, P. Y., Y. Li, H. B. Richards, F. S. Chan, H. Zhuang, S. Narain, E. J. Butfiloski, E. S. Sobel, W. H. Reeves, and M. S. Segal. 2007. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 56:3759-3769.
15. Blanco, P., A. K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294:1540-1543.
16. Crow, M. K., and K. A. Kirou. 2004. Interferon-alpha in systemic lupus erythematosus. Curr. Opin. Rheumatol. 16:541-547.
17. Barrat, F. J., T. Meeker, J. H. Chan, C. Guiducci, and R. L. Coffman. 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37:3582-3586.
18. Lian, Z. X., K. Kikuchi, G. X. Yang, A. A. Ansari, S. Ikehara, and M. E. Gershwin. 2004. Expansion of bone marrow IFN-alpha-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-alpha in NZB bone marrow. J. Immunol. 173:5283-5289.
19. Lu, Q., N. Shen, X. M. Li, and S. L. Chen. 2007. Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun. 8:590-603.
20. Mathian, A., A. Weinberg, M. Gallegos, J. Banchereau, and S. Koutouzov. 2005. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J. Immunol. 174:2499-2506.
21. Hron, J. D., and S. L. Peng. 2004. Type I IFN protects against murine lupus. J. Immunol. 173:2134-2142.
22. Schwarting, A., K. Paul, S. Tschirner, J. Menke, T. Hansen, W. Brenner, V. R. Kelley, M. Relle, and P. R. Galle. 2005. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. 16:3264-3272.
23. Thacker, S., D. Duquaine, J. Park, and M. J. Kaplan. 2010. Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus 19:288-299.
24. Asahara, T., T. Murohara, A. Sullivan, M. Silver, R. van der Zee, T. Li, B. Witzenbichler, G. Schatteman, and J. M. Isner. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967.
25. Gill, M., S. Dias, K. Hattori, M. L. Rivera, D. Hicklin, L. Witte, L. Girardi, R. Yurt, H. Himel, and S. Rafii. 2001. Vascular trauma induces rapid but transient mobilization of VEGFR2 (+) AC133 (+) endothelial precursor cells. Circ. Res. 88:167-174.
26. Rosenzweig, A. 2003. Endothelial progenitor cells. N. Engl. J. Med. 348:581-582.
27. Urbich, C., A. Aicher, C. Heeschen, E. Dernbach, W. K. Hofmann, A. M. Zeiher, and S. Dimmeler. 2005. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 39:733-742.
28. Urbich, C., C. Heeschen, A. Aicher, E. Dernbach, A. M. Zeiher, and S. Dimmeler. 2003. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108:2511-2516.
29. George, J., I. Herz, E. Goldstein, S. Abashidze, V. Deutch, A. Finkelstein, Y. Michowitz, H. Miller, and G. Keren. 2003. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler. Thromb. Vasc. Biol. 23: e57-e60.
30. Vasa, M., S. Fichtlscherer, A. Aicher, K. Adler, C. Urbich, H. Martin, A. M. Zeiher, and S. Dimmeler. 2001. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89: E1-E7.
31. Werner, N., and G. Nickenig. 2006. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler. Thromb. Vasc. Biol. 26:257-266.
32. Kirou, K. A., C. Lee, S. George, K. Louca, I. G. Papagiannis, M. G. Peterson, N. Ly, R. N. Woodward, K. E. Fry, A. Y. Lau, et al. 2004. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50:3958-3967.
33. Dinney, C. P., D. R. Bielenberg, P. Perrotte, R. Reich, B. Y. Eve, C. D. Bucana, and I. J. Fidler. 1998. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 58:808-814.
34. Lindner, D. J., and E. C. Borden. 1997. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int. J. Cancer 71:456-461.
35. Ozawa, S., H. Shinohara, H. O. Kanayama, C. J. Bruns, C. D. Bucana, L. M. Ellis, D. W. Davis, and I. J. Fidler. 2001. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferonalpha. Neoplasia 3:154-164.
36. Persano, L., L. Moserle, G. Esposito, V. Bronte, V. Barbieri, M. Iafrate, M. P. Gardiman, P. Larghero, U. Pfeffer, E. Naschberger, et al. 2009. Interferonalpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis 30:851-860.
37. Raig, E. T., N. B. Jones, K. A. Varker, K. Benniger, M. R. Go, J. L. Biber, G. B. Lesinski, and W. E. Carson, III. 2008. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J. Interferon Cytokine Res. 28:553-561.
38. Sidky, Y. A., and E. C. Borden. 1987. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res. 47:5155-5161.
39. von Marschall, Z., A. Scholz, T. Cramer, G. Schäfer, M. Schirner, K. Oberg, B. Wiedenmann, M. Höcker, and S. Rosewicz. 2003. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 95:437-448.
40. Wu, W. Z., H. C. Sun, Y. F. Shen, J. Chen, L. Wang, Z. Y. Tang, G. Iliakis, and K. D. Liu. 2005. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J. Cancer Res. Clin. Oncol. 131:169-178.
41. Tan, E. M., A. S. Cohen, J. F. Fries, A. T. Masi, D. J. McShane, N. F. Rothfield, J. G. Schaller, N. Talal, and R. J. Winchester. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25:1271-1277.
42. Bombardier, C., D. D. Gladman, M. B. Urowitz, D. Caron, C. H. Chang; The Committee on Prognosis Studies in SLE. 1992. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 35:630-640.
43. Rehman, J., J. Li, L. Parvathaneni, G. Karlsson, V. R. Panchal, C. J. Temm, J. Mahenthiran, and K. L. March. 2004. Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells. J. Am. Coll. Cardiol. 43:2314-2318.
44. Schmeisser, A., C. D. Garlichs, H. Zhang, S. Eskafi, C. Graffy, J. Ludwig, R. H. Strasser, and W. G. Daniel. 2001. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc. Res. 49:671-680.
45. Rohde, E., C. Malischnik, D. Thaler, T. Maierhofer, W. Linkesch, G. Lanzer, C. Guelly, and D. Strunk. 2006. Blood monocytes mimic endothelial progenitor cells. Stem Cells 24:357-367.
46. Hua, J., K. Kirou, C. Lee, and M. K. Crow. 2006. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54:1906-1916.
47. Schmid, H., A. Boucherot, Y. Yasuda, A. Henger, B. Brunner, F. Eichinger, A. Nitsche, E. Kiss, M. Bleich, H. J. Gröne, et al; European Renal cDNA Bank (ERCB) Consortium. 2006. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55:2993-3003.
48. Wiggins, J. E., S. R. Patel, K. A. Shedden, M. Goyal, B. L. Wharram, S. Martini, M. Kretzler, and R. C. Wiggins. 2010. NFkappaB promotes inflammation, coagulation, and fibrosis in the aging glomerulus. J. Am. Soc. Nephrol. 21:587-597.
49. Weening, J. J., V. D. D'Agati, M. M. Schwartz, S. V. Seshan, C. E. Alpers, G. B. Appel, J. E. Balow, J. A. Bruijn, T. Cook, F. Ferrario, et al; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. 2004. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65:521-530.
50. Seckinger, P., J. W. Lowenthal, K. Williamson, J. M. Dayer, and H. R. MacDonald. 1987. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J. Immunol. 139:1546-1549.
51. Eisenberg, S. P., R. J. Evans, W. P. Arend, E. Verderber, M. T. Brewer, C. H. Hannum, and R. C. Thompson. 1990. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343:341-346.
52. Asahara, T., T. Takahashi, H. Masuda, C. Kalka, D. Chen, H. Iwaguro, Y. Inai, M. Silver, and J. M. Isner. 1999. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18:3964-3972.
53. Kariuki, S. N., K. A. Kirou, E. J. MacDermott, L. Barillas-Arias, M. K. Crow, and T. B. Niewold. 2009. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J. Immunol. 182:34-38.
54. Niewold, T. B., J. E. Adler, S. B. Glenn, T. J. Lehman, J. B. Harley, and M. K. Crow. 2008. Age-and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum. 58:2113-2119.
55. Fan, Y., J. Ye, F. Shen, Y. Zhu, Y. Yeghiazarians, W. Zhu, Y. Chen, M. T. Lawton, W. L. Young, and G. Y. Yang. 2008. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J. Cereb. Blood Flow Metab. 28:90-98.
56. Li, B., A. Vincent, J. Cates, D. M. Brantley-Sieders, D. B. Polk, and P. P. Young. 2009. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 69:338-348.
57. Rohde, E., C. Bartmann, K. Schallmoser, A. Reinisch, G. Lanzer, W. Linkesch, C. Guelly, and D. Strunk. 2007. Immune cells mimic the morphology of endothelial progenitor colonies in vitro. Stem Cells 25:1746-1752.
58. Rosell, A., K. Arai, J. Lok, T. He, S. Guo, M. Navarro, J. Montaner, Z. S. Katusic, and E. H. Lo. 2009. Interleukin-1beta augments angiogenic responses of murine endothelial progenitor cells in vitro. J. Cereb. Blood Flow Metab. 29:933-943.
59. Qin, S. L., T. S. Li, M. Takahashi, and K. Hamano. 2006. In vitro assessment of the effect of interleukin-1beta on angiogenic potential of bone marrow cells. Circ. J. 70:1195-1199.
60. Antoni, G., R. Presentini, F. Perin, A. Tagliabue, P. Ghiara, S. Censini, G. Volpini, L. Villa, and D. Boraschi. 1986. A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. J. Immunol. 137:3201-3204.
61. Dinarello, C. A. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27:519-550.
62. Nakae, S., Y. Komiyama, H. Yokoyama, A. Nambu, M. Umeda, M. Iwase, I. Homma, K. Sudo, R. Horai, M. Asano, and Y. Iwakura. 2003. IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Int. Immunol. 15:483-490.
63. Costes, V., M. Portier, Z. Y. Lu, J. F. Rossi, R. Bataille, and B. Klein. 1998. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br. J. Haematol. 103:1152-1160.
64. Mangan, D. F., and S. M. Wahl. 1991. Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and proinflammatory cytokines. J. Immunol. 147:3408-3412.
65. Marshall, J. C., S. H. Jia, J. Parodo, and R. W. Watson. 2008. Interleukin-1beta mediates LPS-induced inhibition of apoptosis in retinoic acid-differentiated HL-60 cells. Biochem. Biophys. Res. Commun. 369:532-538.
66. Cohen, G. M. 1997. Caspases: the executioners of apoptosis. Biochem. J. 326:1-16.
67. Dai, Y., M. Xu, Y. Wang, Z. Pasha, T. Li, and M. Ashraf. 2007. HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia. J. Mol. Cell. Cardiol. 42:1036-1044.
68. Goldberg-Cohen, I., H. Furneauxb, and A. P. Levy. 2002. A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR. J. Biol. Chem. 277:13635-13640.
69. Brennan, C. M., and J. A. Steitz. 2001. HuR and mRNA stability. Cell. Mol. Life Sci. 58:266-277.
70. Goodbourn, S., L. Didcock, and R. E. Randall. 2000. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81:2341-2364.
71. Hjortsberg, L., C. Lindvall, M. Corcoran, V. Arulampalam, D. Chan, L. Thyrell, M. Nordenskjold, D. Grandér, and K. Pokrovskaja. 2007. Phosphoinositide 3-kinase regulates a subset of interferon-alpha-stimulated genes. Exp. Cell Res. 313:404-414.
72. Manzi, S., E. N. Meilahn, J. E. Rairie, C. G. Conte, T. A. Medsger, Jr., L. Jansen-McWilliams, R. B. D'Agostino, and L. H. Kuller. 1997. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145:408-415.
73. Werner, N., S. Kosiol, T. Schiegl, P. Ahlers, K. Walenta, A. Link, M. Böhm, and G. Nickenig. 2005. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353:999-1007.
74. Grisar, J., D. Aletaha, C. W. Steiner, T. Kapral, S. Steiner, D. Seidinger, G. Weigel, I. Schwarzinger, W. Wolozcszuk, G. Steiner, and J. S. Smolen. 2005. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111:204-211.
75. Surdacki, A., E. Marewicz, E. Wieczorek-Surdacka, T. Rakowski, G. Szastak, J. Pryjma, D. Dudek, and J. S. Dubiel. 2009. Synergistic effects of asymmetrical dimethyl-l-arginine accumulation and endothelial progenitor cell deficiency on renal function decline during a 2-year follow-up in stable angina. Nephrol. Dial. Transplant
76. Krenning, G., P. Y. Dankers, J. W. Drouven, F. Waanders, C. F. Franssen, M. J. van Luyn, M. C. Harmsen, and E. R. Popa. 2009. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am. J. Physiol. Renal Physiol. 296: F1314-F1322.
77. Albini, A., C. Marchisone, F. Del Grosso, R. Benelli, L. Masiello, C. Tacchetti, M. Bono, M. Ferrantini, C. Rozera, M. Truini, et al. 2000. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am. J. Pathol. 156:1381-1393.
78. Lara, P. N., Jr., D. I. Quinn, K. Margolin, F. J. Meyers, J. Longmate, P. Frankel, P. C. Mack, C. Turrell, P. Valk, J. Rao, et al; California Cancer Consortium. 2003. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin. Cancer Res. 9:4772-4781.
79. Oliveira, I. C., P. J. Sciavolino, T. H. Lee, and J. Vilcek. 1992. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA 89:9049-9053.
80. Rosewicz, S., K. Detjen, A. Scholz, and Z. von Marschall. 2004. Interferonalpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 80(Suppl. 1):85-93.
81. Suzuki, H., H. Takemura, and H. Kashiwagi. 1995. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus: enhanced production by monocytes and correlation with disease activity. Arthritis Rheum. 38:1055-1059.
82. Andersen, L. S., J. Petersen, M. Svenson, and K. Bendtzen. 1999. Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE. Autoimmunity 30:235-242.
83. Coclet-Ninin, J., J. M. Dayer, and D. Burger. 1997. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine Netw. 8:345-349.
84. Cotler, S. J., T. Craft, M. Ferris, M. Morrisey, J. McCone, K. R. Reddy, A. Conrad, D. M. Jensen, J. Albrecht, and M. W. Taylor. 2002. Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1. J. Interferon Cytokine Res. 22:549-554.
85. Naveau, S., D. Emilie, E. Borotto, A. Portier, Y. Lazizi, V. Giraud, L. Grangeot-Keros, F. Capron, P. Galanaud, and J. C. Chaput. 1997. Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment. J. Hepatol. 27:272-275.
86. Jungo, F., J. M. Dayer, C. Modoux, N. Hyka, and D. Burger. 2001. IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine 14:272-282.
87. Palmer, G., F. Mezin, C. E. Juge-Aubry, C. Plater-Zyberk, C. Gabay, and P. A. Guerne. 2004. Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann. Rheum. Dis. 63:43-49.
88. Wan, L., C. W. Lin, Y. J. Lin, J. J. Sheu, B. H. Chen, C. C. Liao, Y. Tsai, W. Y. Lin, C. H. Lai, and F. J. Tsai. 2008. Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J. Cell. Mol. Med. 12:876-888.
89. Kommineni, V. K., C. N. Nagineni, A. William, B. Detrick, and J. J. Hooks. 2008. IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem. Biophys. Res. Commun. 374:479-484.
90. Lee, C., H. K. Lim, J. Sakong, Y. S. Lee, J. R. Kim, and S. H. Baek. 2006. Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1beta and IL-6 production. Mol. Pharmacol. 69:1041-1047.
91. Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, and R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100:2645-2650.
92. Coxon, A., B. Bolon, J. Estrada, S. Kaufman, S. Scully, A. Rattan, D. Duryea, Y. L. Hu, K. Rex, E. Pacheco, et al. 2002. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum. 46:2604-2612.
93. Daculsi, R., M. Rémy-Zolghadri, M. Grellier, V. Conrad, P. Fernandez, R. Bareille, and L. Bordenave. 2007. Signal transduction and procoagulant state of human cord blood-progenitor-derived endothelial cells after interleukin-1alpha stimulation. Endothelium 14:163-171.
94. Lee, H. T., J. G. Lee, M. Na, and E. P. Kay. 2004. FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells. J. Biol. Chem. 279:32325-32332.
95. Carmi, Y., E. Voronov, S. Dotan, N. Lahat, M. A. Rahat, M. Fogel, M. Huszar, M. R. White, C. A. Dinarello, and R. N. Apte. 2009. The role of macrophagederived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183:4705-4714.
96. Nasu, K., H. Itoh, A. Yuge, Y. Kawano, J. Yoshimatsu, and H. Narahara. 2006. Interleukin-1beta regulates vascular endothelial growth factor and soluble fmslike tyrosine kinase-1 secretion by human oviductal epithelial cells and stromal fibroblasts. Gynecol. Endocrinol. 22:495-500.
97. Rogers, M. S., R. M. Rohan, A. E. Birsner, and R. J. D'Amato. 2003. Genetic loci that control vascular endothelial growth factor-induced angiogenesis. FASEB J. 17:2112-2114.
98. Amano, K., M. Okigaki, Y. Adachi, S. Fujiyama, Y. Mori, A. Kosaki, T. Iwasaka, and H. Matsubara. 2004. Mechanism for IL-1 beta-mediated neovascularization unmasked by IL-1 beta knock-out mice. J. Mol. Cell. Cardiol. 36:469-480.
99. Henrich, D., C. Seebach, K. Wilhelm, and I. Marzi. 2007. High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. J. Surg. Res. 142:13-19.
100. Mohty, M., A. Vialle-Castellano, J. A. Nunes, D. Isnardon, D. Olive, and B. Gaugler. 2003. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J. Immunol. 171:3385-3393.
101. Kruse, M., E. Meinl, G. Henning, C. Kuhnt, S. Berchtold, T. Berger, G. Schuler, and A. Steinkasserer. 2001. Signaling lymphocytic activation molecule is expressed on mature CD83+ dendritic cells and is up-regulated by IL-1 beta. J. Immunol. 167:1989-1995.
102. Luft, T., M. Jefford, P. Luetjens, H. Hochrein, K. A. Masterman, C. Maliszewski, K. Shortman, J. Cebon, and E. Maraskovsky. 2002. IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation. J. Immunol. 168:713-722.
103. Schoppet, M., S. Henser, V. Ruppert, T. Stübig, N. Al-Fakhri, B. Maisch, and L. C. Hofbauer. 2007. Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent. J. Cell. Biochem. 100:1430-1439.
104. Wesa, A. K., and A. Galy. 2001. IL-1 beta induces dendritic cells to produce IL-12. Int. Immunol. 13:1053-1061.
105. Turnquist, H. R., T. L. Sumpter, A. Tsung, A. F. Zahorchak, A. Nakao, G. J. Nau, F. Y. Liew, D. A. Geller, and A. W. Thomson. 2008. IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J. Immunol. 181:62-72.
106. Kaplan, M. J., Q. Lu, A. Wu, J. Attwood, and B. Richardson. 2004. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J. Immunol. 172:3652-3661.
107. Han, J. W., K. Shimada, W. Ma-Krupa, T. L. Johnson, R. M. Nerem, J. J. Goronzy, and C. M. Weyand. 2008. Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascular inflammation. Circ. Res. 102:546-553.
108. Denny, M. F., S. Yalavarthi, W. Zhao, S. G. Thacker, M. Anderson, A. R. Sandy, W. J. McCune, and M. J. Kaplan. 2010. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 184:3284-3297.
109. Crow, M. K., and J. Wohlgemuth. 2003. Microarray analysis of gene expression in lupus. Arthritis Res. Ther. 5:279-287.
110. Kang, D. H., J. Hughes, M. Mazzali, G. F. Schreiner, and R. J. Johnson. 2001. Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J. Am. Soc. Nephrol. 12:1448-1457.
111. Bohle, A., S. Mackensen-Haen, and M. Wehrmann. 1996. Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press. Res. 19:191-195.
112. Doi, K., E. Noiri, and T. Fujita. 2010. Role of vascular endothelial growth factor in kidney disease. Curr. Vasc. Pharmacol. 8:122-128.
113. Gröne, H. J., M. Simon, and E. F. Gröne. 1995. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J. Pathol. 177:259-267.
114. Cooper, M. E., D. Vranes, S. Youssef, S. A. Stacker, A. J. Cox, B. Rizkalla, D. J. Casley, L. A. Bach, D. J. Kelly, and R. E. Gilbert. 1999. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48:2229-2239.
115. Schrijvers, B. F., A. Flyvbjerg, and A. S. De Vriese. 2004. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 65:2003-2017.
116. Jonkers, I. J., and M. van Buren. 2009. Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clin. Exp. Nephrol. 13:397-401.
117. Hohenstein, B., B. Hausknecht, K. Boehmer, R. Riess, R. A. Brekken, and C. P. Hugo. 2006. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 69:1654-1661.
118. Lindenmeyer, M. T., M. Kretzler, A. Boucherot, S. Berra, Y. Yasuda, A. Henger, F. Eichinger, S. Gaiser, H. Schmid, M. P. Rastaldi, et al. 2007. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J. Am. Soc. Nephrol. 18:1765-1776.
119. Avihingsanon, Y., T. Benjachat, A. Tassanarong, P. Sodsai, V. Kittikovit, and N. Hirankarn. 2009. Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis. Kidney Int. 75:1340-1348.
120. Buraczynska, M., P. Ksiazek, P. Kubit, and W. Zaluska. 2006. Interleukin-1 receptor antagonist gene polymorphism affects the progression of chronic renal failure. Cytokine 36:167-172.
121. Shu, K. H., S. H. Lee, C. H. Cheng, M. J. Wu, and J. D. Lian. 2000. Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy. Kidney Int. 58:783-789.
122. Fairhurst, A. M., C. Xie, Y. Fu, A. Wang, C. Boudreaux, X. J. Zhou, R. Cibotti, A. Coyle, J. E. Connolly, E. K. Wakeland, and C. Mohan. 2009. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J. Immunol. 183:6831-6838.
123. Fairhurst, A. M., A. Mathian, J. E. Connolly, A. Wang, H. F. Gray, T. A. George, C. D. Boudreaux, X. J. Zhou, Q. Z. Li, S. Koutouzov, et al. 2008. Systemic IFN-alpha drives kidney nephritis in B6. Sle123 mice. Eur. J. Immunol. 38:1948-1960.
124. Neven, B., I. Marvillet, C. Terrada, A. Ferster, N. Boddaert, V. Couloignier, G. Pinto, A. Pagnier, C. Bodemer, B. Bodaghi, et al. 2010. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatalonset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 62:258-267.
125. Mertens, M., and J. A. Singh. 2009. Anakinra for rheumatoid arthritis: a systematic review. J. Rheumatol. 36:1118-1125.
126. Moosig, F., R. Zeuner, C. Renk, and J. O. Schröder. 2004. IL-1RA in refractory systemic lupus erythematosus. Lupus 13:605-606.
127. Ostendorf, B., C. Iking-Konert, K. Kurz, G. Jung, O. Sander, and M. Schneider. 2005. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. 64:630-633.
128. Mavragani, C. P., T. B. Niewold, N. M. Moutsopoulos, S. R. Pillemer, S. M. Wahl, and M. K. Crow. 2007. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum. 56:3995-4004.
129. Emamian, E. S., J. M. Leon, C. J. Lessard, M. Grandits, E. C. Baechler, P. M. Gaffney, B. Segal, N. L. Rhodus, and K. L. Moser. 2009. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun. 10:285-296.
130. Kim, D., A. Peck, D. Santer, P. Patole, S. M. Schwartz, J. A. Molitor, F. C. Arnett, and K. B. Elkon. 2008. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum. 58:2163-2173.
131. Airò, P., C. Ghidini, C. Zanotti, M. Scarsi, R. Cattaneo, L. Caimi, and L. Imberti. 2008. Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis. J. Rheumatol. 35:2192-2200.
132. Eriksen, K. W., P. Lovato, L. Skov, T. Krejsgaard, K. Kaltoft, C. Geisler, and N. Ødum. 2005. Increased sensitivity to interferon-alpha in psoriatic T cells. J. Invest. Dermatol. 125:936-944.
133. Nestle, F. O., and M. Gilliet. 2005. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J. Invest. Dermatol. 125: xiv-xv.